Atossa Therapeutics (FRA:YAG2) 3-Year Book Growth Rate : 8.70% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics 3-Year Book Growth Rate?

Atossa Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €0.63.

During the past 12 months, Atossa Therapeutics's average Book Value per Share Growth Rate was -23.60% per year. During the past 3 years, the average Book Value per Share Growth Rate was 8.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was -11.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was -40.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Atossa Therapeutics was 55.30% per year. The lowest was -66.50% per year. And the median was -36.95% per year.

Competitive Comparison of Atossa Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Atossa Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atossa Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's 3-Year Book Growth Rate falls into.

Atossa Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Atossa Therapeutics (FRA:YAG2) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Atossa Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (FRA:YAG2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines